Next, we subjected the CRC cell line HCT116 harboring wild-type p53 (HCT116 p53+/+) and p53-deficient HCT116 cells (HCT116 p53-/-) to treatment with the MDM2 inhibitor Nutlin-3 or the chemotherapeutic agents etoposide, doxorubicin (DOXO) and 5-fluorouracil (5-FU; Figure 3B-3E). Here, TP53 is linked to colorectal carcinoma.